News & Events
Driving agility to improve productivity in medical affairs
Dr. Rav Seeruthun, the chief medical officer and co-founder of health-equity.ai, and ZS’s Sunil John, (Global Medical Affairs Lead, ZS Associates) recently authored a new white paper that explores the rapid transformation of medical affairs and thus the critical need for agility. They specifically discuss quantifying agility for practice change, enhancing productivity and optimizing field medical engagements in today’s complex landscape. Read the white paper on ZS.com.
2024 PING Innovation Award Winner: health-equity.ai
Paul Gershlick, PING chair and Head of Pharmaceuticals and Life Sciences at VWV, announced health-equity.ai as the winner.
health-equity.ai is driven by the mission to harness AI for good, analysing vast healthcare datasets to identify and address health disparities. With the proliferation of artificial intelligence throughout the pharmaceutical ecosystem, health.equity.ai has uniquely leveraged this technology.
The platform’s efforts are pivotal in regions with significant health inequalities, such as in certain cancer types where disparities in occurrences and death rates are stark. Some UK regions see 50% more occurrences and 40% higher death rates than the national average. Similar issues are seen in other therapy areas such as diabetes and rare diseases. Collaborating with pharma companies like Beigene and Roche Diabetes Care, health-equity.ai is promoting fair healthcare access and enhances patient care.
Accepting the award were Co-Founder and Chief Medical Officer, Dr. Rav Seeruthun, and Co-Founder and Chief Technology Officer, Professor Ian Colwill. Rav commented, “We are honoured and thrilled to receive this prestigious award. Using Artificial Intelligence, our team are able to analyse massive healthcare datasets to identify patterns of health inequalities. Our mission is to create partnerships to ‘level up’ these inequalities and ensure better outcomes for more patients.”
He added, “We are grateful to VWV, the organisers of the event, and the selection committee for recognising our achievement and potential. We would like to thank Paul Gershlick and Adrian Hawkins OBE, Chair at Hertfordshire Local Enterprise Partnership, for presenting us the award at the PING Conference 2024”
Paul Gershlick, alongside Adrian Hawkins OBE, Chair of the Hertfordshire Local Enterprise Partnership, presented the award. Paul commented, “At its core, health-equity.AI is driven by the mission to harness AI for good, using it as a tool to analyse vast healthcare datasets and identify patterns of health disparities. By doing so, it aims to level the playing field. The dedication to fairness, AI expertise, and potential for global impact make health-equity.ai a shining example of innovation for the greater good.”
Paul further commented, “health-equity.ai offers hope that, through technology and collaboration, we can create a world where every individual, regardless of their background, has an equal opportunity to live a healthy life”.
Join us at The Royal Society of Medicine event on 23rd April 2024 (virtual)
As Artificial Intelligence (AI) develops faster than ever, with generative AI, clinicians must keep up-to-date with its impact on their patients, care pathways and their careers.
This webinar will explore how AI is changing healthcare. Learn from innovators and businesses already using it to understand the state of NHS and social care data, and how it can be used to reduce inequalities, those subspecialties using AI with examples across radiology, cardiology, mental health and surgery, its impact on doctor-patient relationships, and regulations.
By attending this webinar, participants will learn:
- The importance of clean data and linking data so it can be used for AI
- How AI is changing the dr-patient relationship
- What is needed to get regulatory approval for software
https://www.rsm.ac.uk/events/digital-health/2023-24/tes02/
Join us at The Pharma Industry Network Group (PING) Conference on 10th June 2024
AI is currently dominating discussions. It has already changed how we operate and is poised to significantly reshape the world. McKinsey’s research points to potential opportunities worth $100 billion annually for the pharmaceutical industry. However, alongside these opportunities come significant threats and risks. AI’s influence will impact every aspect of the pharmaceutical ecosystem, spanning from drug discovery and repurposing to sourcing, manufacturing, quality assurance, supply chain management, and engagement with healthcare professionals and patients.
Consequently, AI in pharma is an unavoidable subject. At this year’s PING Conference, attendees will have the chance to learn from industry experts who will delve into the practical implications of AI in pharma. Covering insightful case studies, delegates will hear about both risks and opportunities leaving them better placed to face and prepare for what is coming.
https://www.vwv.co.uk/ping-2024